Galapagos (NASDAQ:GLPG) Stock Rating Upgraded by Wall Street Zen

Galapagos (NASDAQ:GLPG) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Sunday.

GLPG has been the subject of several other research reports. Leerink Partnrs raised shares of Galapagos from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 22nd. Royal Bank Of Canada increased their price objective on Galapagos from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research report on Friday, November 7th. Weiss Ratings restated a “sell (d)” rating on shares of Galapagos in a research report on Wednesday, October 8th. Sanford C. Bernstein assumed coverage on Galapagos in a report on Wednesday, November 26th. They set a “hold” rating for the company. Finally, Leerink Partners set a $40.00 price objective on Galapagos and gave the stock an “outperform” rating in a research report on Tuesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $31.33.

Galapagos Trading Down 1.8%

NASDAQ GLPG opened at $31.11 on Friday. The business’s fifty day simple moving average is $31.94 and its 200-day simple moving average is $31.47. Galapagos has a 52 week low of $22.36 and a 52 week high of $37.78.

Hedge Funds Weigh In On Galapagos

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE grew its position in Galapagos by 2.1% in the 3rd quarter. Bank of America Corp DE now owns 30,949 shares of the biotechnology company’s stock valued at $1,072,000 after acquiring an additional 643 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Galapagos by 79.4% in the third quarter. GAMMA Investing LLC now owns 1,473 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 652 shares in the last quarter. Two Sigma Investments LP increased its stake in Galapagos by 3.7% during the 3rd quarter. Two Sigma Investments LP now owns 22,459 shares of the biotechnology company’s stock worth $778,000 after buying an additional 800 shares during the period. State of Wyoming acquired a new stake in Galapagos during the 2nd quarter worth approximately $28,000. Finally, American Century Companies Inc. lifted its holdings in Galapagos by 7.7% during the 1st quarter. American Century Companies Inc. now owns 27,839 shares of the biotechnology company’s stock worth $699,000 after buying an additional 1,987 shares in the last quarter. 32.46% of the stock is currently owned by hedge funds and other institutional investors.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.